This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Agios Pharmaceuticals Inc. (therapies for cancer and rare genetic diseases) netted $277.2mm through a follow-on public offering of 9.49mm common shares (including full exercise of the overallotment) at $31 each. The company will use the funds for regulatory and commercial activities of Tibsovo in Europe for relapsed or refractory acute myeloid leukemia (AML) and in the US for second line or later cholangiocarcinoma; Phase III enrollment in the AGILE trial of ivosidenib in combination with azacitidine in frontline AML patients ineligible for chemotherapy; enrollment in the Phase III trial combining ivosidenib or enasidenib and standard induction and consolidation chemotherapy in frontline AML patients; enrollment in the Phase I trial of ivosidenib in myelodysplastic syndrome (MDS); initiation and enrollment of the Phase III INDIGO trial with vorasidenib in low grade glioma; enrollment and data readouts of the ACTIVATE and ACTIVATE-T pivotal trials and global launch preparation activities for mitapivat in adults with PK deficiency; enrollment and data readout of the Phase II trial of mitapivat in thalassemia; enrollment in two dose expansion arms of a Phase I study of AG270 in MTAP-deleted cancers and Phase I trial for AG636 in lymphoma; IND-enabling activities and a Phase I trial for its next-generation PKR activator; and to advance its late-stage preclinical pipeline.
Drug Discovery Tools
Already a Strategic Transactions subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?